AKBA ▲ +1.1% - Akebia Therapeutics, Inc. $AKBA - Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases Akebia Therapeutics rose 1.1% following its announcement that the first patient has been dosed in a Phase 2 basket trial of ebribafusp, its investigational therapy targeting rare complement-mediated kidney diseases. The enrollment milestone advances the company's clinical pipeline in an area of significant unmet medical need. 14-SEP-2026 08:01 AM ET